Once limited to ankylosing spondylitis (AS), the axial spondyloarthritis (AxSpA) therapy market is undergoing rapid change as the definition of the disease expands beyond those with detectable spinal abnormalities and into the population of nonradiographic axial spondyloarthritis (nr-AxSpA) patients. TNF-alpha inhibitors are the standard of care in AS patients who do not respond to conventional therapies such as NSAIDs. Although nr-AxSpA is still not officially recognized in the United States as a stand-alone indication, physicians report that they manage their nr-AxSpA patients in a similar way to their AS patients. In 2016, the IL-17 inhibitor Cosentyx became the first non-TNF biologic approved for AS and the first drug to bring a new mechanism of action to this indication in more than a decade. Current Treatment | Axial Spondyloarthritis | US is a primary market research-based report that explores current physician prescribing practices in the treatment of both AS and nr-AxSpA. It examines the use of biologics as well as conventional therapies in both indications, the factors that drive physicians’ use of key brands, and any anticipated changes in use in the coming year.
- In which line of therapy is Cosentyx being used?
- How long do physicians wait to prescribe a biologic for their AxSpA patients?
- What is the brand-level patient share of key biologics in AS and nr-AxSpA?
- Markets covered: United States.
- Methodology: Surveys of 100 rheumatologists, completed in February 2017.
- Indication coverage: Axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
- Key drugs covered: Humira, Enbrel, Cimzia, Simponi, Remicade, Cosentyx.